<DrugInformationSummary id="CDR0000775869"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This chemotherapy combination contains the drugs trifluridine and tipiracil hydrochloride. Trifluridine enters cells and gets incorporated into the DNA, which keeps it from being copied. This stops cells from dividing. Tipiracil hydrochloride prevents trifluridine from being broken down in the body so it can kill more cancer cells.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/trifluridine-tipiracilhydrochloride">Trifluridine and Tipiracil Hydrochloride</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000734891">trifluridine and tipiracil hydrochloride</TerminologyLink><GlossaryLink ref="CDR0000775863">trifluridine and tipiracil hydrochloride</GlossaryLink><USBrandNames><USBrandName>Lonsurf</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>try-FLOOR-ih-deen â€¦ ty-PEER-uh-sil HY-droh-KLOR-ide</TermPronunciation><MediaLink ref="CDR0000776471" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000776470" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5beed22-d71d-4c0d-8dca-2c7317d65d85&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Trifluridine and Tipiracil Hydrochloride</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5beed22-d71d-4c0d-8dca-2c7317d65d85&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Trifluridine and tipiracil hydrochloride
         is approved to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444983" dictionary="Cancer.gov" audience="Patient">Colorectal cancer</GlossaryTermRef></Strong> that has spread to other parts of the body. It is used alone or with <GlossaryTermRef href="CDR0000046115" dictionary="Cancer.gov" audience="Patient">bevacizumab</GlossaryTermRef> in patients who have already been treated with a <GlossaryTermRef href="CDR0000386207" dictionary="Cancer.gov" audience="Patient">fluoropyrimidine</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045465" dictionary="Cancer.gov" audience="Patient">oxaliplatin</GlossaryTermRef>, <GlossaryTermRef href="CDR0000635811" dictionary="Cancer.gov" audience="Patient">irinotecan hydrochloride</GlossaryTermRef>, and a <GlossaryTermRef href="CDR0000044474" dictionary="Cancer.gov" audience="Patient">VEGF</GlossaryTermRef> <GlossaryTermRef href="CDR0000046739" dictionary="Cancer.gov" audience="Patient">inhibitor</GlossaryTermRef>.  Patients whose cancer has the <GlossaryTermRef href="CDR0000785884" dictionary="Cancer.gov" audience="Patient">wild-type KRAS gene</GlossaryTermRef> should have also received an <GlossaryTermRef href="CDR0000532303" dictionary="Cancer.gov" audience="Patient">EGFR inhibitor</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000445087" dictionary="Cancer.gov" audience="Patient">Stomach</GlossaryTermRef> <GlossaryTermRef href="CDR0000046216" dictionary="Cancer.gov" audience="Patient">adenocarcinoma</GlossaryTermRef></Strong> or <Strong><GlossaryTermRef href="CDR0000302458" dictionary="Cancer.gov" audience="Patient">gastroesophageal junction</GlossaryTermRef> adenocarcinoma</Strong> (a rare type of <GlossaryTermRef href="CDR0000444989" dictionary="Cancer.gov" audience="Patient">esophageal cancer</GlossaryTermRef>) that has spread to other parts of the body. It is used in patients who have already received at least two treatments with a  fluoropyrimidine and <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef> <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> and either a <GlossaryTermRef href="CDR0000046138" dictionary="Cancer.gov" audience="Patient">taxane</GlossaryTermRef> or irinotecan and, in some cases, <GlossaryTermRef href="CDR0000044945" dictionary="Cancer.gov" audience="Patient">HER2/neu</GlossaryTermRef>-<GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">targeted therapy</GlossaryTermRef>.</ListItem>
   
   </ItemizedList>
  <Para id="_4">Trifluridine and tipiracil hydrochloride
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Trifluridine and Tipiracil Hydrochloride</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/734891">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.37">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a615049.html">Trifluridine and Tipiracil Hydrochloride</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.38"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.39">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/lonsurf-talzenna-cancer-tp53-mutations">Drug Combination May Have Potential for Cancers with TP53 Mutations</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/avastin-lonsurf-improves-survival-colorectal-cancer">Drug Regimen Boosts Survival of People with Advanced Colorectal Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C102554">Find Clinical Trials for Trifluridine And Tipiracil Hydrochloride</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2015-09-25</DateFirstPublished><DateLastModified>2024-04-04</DateLastModified></DrugInformationSummary>
